Make Informed Investment Decisions with Affordable Access to Experts
Another Perspective: Understanding Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by IovanceTicker(s): IOVA
Name: Dr Qiao Li - PhD.
Institution: University of Michigan
- Research Associate Professor & member of the Tumor Immunology Program at the University of Michigan Medical Cancer Center with over 20 years of experience.
- Research focuses on the generation of tumor-reactive T cells for the adoptive immunotherapy of cancer centering on developing new strategies for T cell activation /expansion using monoclonal antibodies and recombinant cytokines.
- A novel protocol based on Dr. Li's effort utilizing anti-CD3/anti-CD28 activated T cells is funded by NIH and is now being used in a clinical trial to treat renal cell cancers at the University of Michigan Medical Center.
Please describe your clinical practice as it relates to cancer immunotherapies.Added By: c_admin
Can you briefly explain TIL as a mechanism of action?Added By: c_admin
What are your thoughts on Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by Iovance?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.